BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 10, 2021 at 8:30 AM ET to discuss results for the first quarter 2021 and provide a business outlook for 2021. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with FDA and Initiate Clinical Study of TARA-002 in Lymphatic Malformations - - Strong Cash, Cash Equivalents and Investments Position of $155M as of March 31, 2021 -

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-Resourced with Cash Runway Expected into the Second Half of 2024 -

Enrolling Patients in Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients Today Announced Three-Part KOL Webinar Series on Its Portfolio of Investigational Targeted Hematology Therapies, Beginning May 2021 On Track to Achieve 2021 Milestones, Including Initiation of SY-1425 and SY-2101 Clinical Trials in 2H 2021 and Additional Dose-Escalation Data for SY-5609 in 3Q 2021

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reported financial results for the first quarter ended March 31, 2021

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 13, 2021, to review its financial results for the quarter ended March 31, 2021 and to provide a Company update.

Leader in virtual medical documentation will share insights into the hybrid human/artificial intelligence (AI) approach to medical notetaking solutions at the virtual conference for healthcare professionals

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced progress with the German regulatory authority to achieve reimbursement for its sugarBEAT® device.